As a part of evaluation of strategic alternatives, Akili, Inc. announced that its board of directors approved a revised operating plan and budget for the remainder of 2024 and related restructuring of the organization to lower operating expenses while focusing on supporting Shionogi?s regulatory and commercialization activities. The Company?s workforce will be reduced by approximately 46% including an elimination of the Company?s marketing and medical affairs teams. In conjunction with this restructuring, the Company has substantially reduced promotional activity for its EndeavorRx and EndeavorOTC products, but plans to continue to support current users of its products and make its products available for purchase.